Advertisement

Topics

"Anthem Blue Cross and Blue Shield in Georgia∨derfield=date∨derval=DESC" News Stories

18:20 EDT 15th July 2019 | BioPortfolio

Here are the most relevant search results for "Anthem Blue Cross and Blue Shield in Georgia∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about Anthem Blue Cross and Blue Shield in Georgia∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Anthem Blue Cross and Blue Shield in Georgia∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list Anthem Blue Cross and Blue Shield in Georgia∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Anthem Blue Cross and Blue Shield in Georgia∨derfield=date∨derval=DESC Companies for you to search.

Showing "Anthem Blue Cross Blue Shield Georgia derfield date" News Articles 1–25 of 7,200+

Monday 15th July 2019

vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral presentation at the 2019 Alzheimer's Association International Conference (AAI


RCH Solutions Introduces Focused Public Cloud Managed Service

The Bio-IT veteran expands support of public Cloud initiatives through new specialty advisory practice designed specifically for biotechs and emerging pharmaceutical companies. WAYNE, Pa. (PRWEB) July 15, 2019 RCH Solutions (RCH), a leading global provider of computational science expertise exclusively for Life Sciences and Healthcare companies, announces the availability of new specialty advisor...

Western Dental Office Opens in Gardena

Western Dental & Orthodontics, one of the nation’s leaders in accessible, affordable oral healthcare and the leading orthodontics provider in the country, today announced the opening of a new Western Dental & Orthodontics office in Gardena. The Gardena office is located at 15515 S. Normandie Avenue at Redondo Beach Blvd. With the addition of the new office, Western Dental now operates...


Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019

Record Annual Revenue of $27 Million HACKENSACK, NJ / ACCESSWIRE / July 15, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2019.

Edifecs to Establish East Coast Presence in Atlanta

The Georgia Department of Economic Development (GDEcD) today announced that Edifecs, Inc., a global health information technology solutions company, plans to hire up to 200 associates in the next three to five years in a new office location in Fulton County. “We are pleased to welcome Edifecs to Atlanta,” said GDEcD Commissioner Pat Wilson. “Georgia has become a magnet for technology-driv...

His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date.  https://buff.ly/2NXAXjv 

His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date.  https://buff.ly/2NXAXjv 

AVROBIO Announces Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease. To date, eight patients have been dosed in the trials – three patients in the Phase 2 FAB-2011 trial and five patients in the...

Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9

Epigenomics AG / Key word(s): Patent/Legal Matter Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9 15-Jul-2019 / 15:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of...

Biden puts forth an elaborate — and aggressive — plan to lower drug prices 

His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date. 

Boston Children’s Hospital Forms Strategic Partnership with Premier Inc.

Boston Children’s Hospital, one of the largest pediatric medical centers in the U.S., has partnered with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to foster optimal management of its supply chain portfolio. Ranked the #1 children's hospital in the nation by U.S. News & World Report, Boston Children’s is the primary pediatric teaching affiliate of Harvard Med...

The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone. https://buff.ly/2NTacwl 

The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone. https://buff.ly/2NTacwl 

LivaNova Receives U.S. FDA 510(k) Clearance for LifeSPARC Advanced Circulatory Support System

The versatile and compact system offers the power and simplicity to support more patients in more places LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Advanced Circulatory Support (ACS) pump and controller, the LifeSPARC system. Derived from more than 20 years ...

State Highlights: Maryland Cites ‘Dickensian’ Abuse Conditions In Suit Against For-Profit Group Homes; Researchers Grapple With Problems Of Diagnosing Rat Lungworm Disease In Hawaii

Media outlets focus on news from Maryland, Delaware, New Jersey, Hawaii, Tennessee, Virginia, Connecticut, California, North Carolina, District of Columbia, New Hampshire, Missouri, Georgia, Washington, Maryland, Oregon, Colorado, Ohio, Florida and West Virginia.

Lynch Syndrome and Urologic Malignancies

Get up-to-date on the most recent developments regarding lynch syndrome-associated urologic malignancies. Current Opinion in Urology

New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

CD8+ T Cell Reactivity Against 90% of Personalized Neoantigen Targets Confirmed in First of Two Patients Proof-of-Mechanism for Off-the-Shelf ADXS-HOT Program with CD8+ T Cells Against Hotspot Mutations Antigen Spreading Confirmed Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today...

Apyx Medical Corporation Announces Appointment of Four Members to its Medical Advisory Board

Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, which is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the appointment of four members to its Medical Advisory Board. “Apyx Medica...

BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment

- Professor Jacky Smith from the University of Manchester to lead live webcast - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on T...

AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease

– 87% reduction in average number of Gb3 inclusions in first kidney biopsy taken one year post-treatment, the primary efficacy endpoint in the Phase 2 trial – Plasma lyso-Gb3 consistently reduced 33% to 41% below baseline enzyme replacement therapy (ERT) levels in the first four Phase 1 patients – Durability observed across multiple biomarkers, sustained at more than two years for the f...

Human medicines European public assessment report (EPAR): Ambrisentan Mylan, ambrisentan, Hypertension, Pulmonary, Date of authorisation: 20/06/2019, Status: Authorised

Human medicines European public assessment report (EPAR): Ambrisentan Mylan, ambrisentan, Hypertension, Pulmonary, Date of authorisation: 20/06/2019, Status: Authorised

In a small study, a cancer vaccine assist beats immunotherapy drugs alone

The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone.

Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million

Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merg...

Sunday 14th July 2019

Innovate Biopharmaceuticals Announces Corporate Update and Expected Date for Second Quarter Earnings Release

Innovate undertakes succession planning for a chief executive officer Finance team strengthened and well positioned for future growth Second quarter earnings release expected August 8, 2019 RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and infla...

Baby blue-tongues are born smart

(Macquarie University) Young Australian eastern blue-tongue lizards (Tiliqua scincoides) are every bit as clever as adults, researchers have found. Life is hard for baby blue-tongues. As soon as they are born, they are on their own, with neither parental support nor protection. Adults of the species can grow to 600 millimetres long and enjoy the benefits of thick scales and a powerful bite, but th...

Scientists explore blood flow bump that happens when our neurons are significantly activated

(Medical College of Georgia at Augusta University) When a group of our neurons get activated by thinking hard about a math problem or the vibrant colors of an exotic flower, within a single second blood flow to those brain cells increases a bit.

Qiagen 132006 EasyXtal 15-Well Tool (20)

AU $145.24End Date: Wednesday Aug-14-2019 19:19:24 ESTBuy It Now for only: AU $145.24Buy It Now | Add to watch list Biotech365 : Qiagen 132006 EasyXtal 15-Well Tool (20) BioMarketplace You want to propose your products or a Biotech Company, a … Continue reading →


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks